Business
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. Two poster presentations at AANEM will highlight preclinical and in vitro data describing the potentially differentiated profile of DNTH103 in disease models of generalized Myasthenia Gravis (gMG) and Chronic Demyelinating Polyneuropathy (CIDP), in addition to head-to-head affinity and pharmacodynamic (PD) potency data for DNTH103 compared to riliprubart. Dianthus Presentations at AANEM: October 16, 2024, 6:15-6:45 PM ET & October 17, 2024, 2:45-3:15 PM ETDNTH103 Shows Sustainable Inhibition of Complement and Prevents Nerve Conduction Velocity Impairment in a Preclinical Model of CIDPPoster #201 October 16, 2024, 6:15-6:45 PM ET & October 17, 2024, 9:30-10:00 AM ETDNTH103, A Potentially Safer and More Convenient Novel, Investigational Therapy for Generalized Myasthenia GravisPoster #297 These posters will be made available in the Scientific Publications section of the Dianthus website after they are presented. About DNTH103DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. DNTH103 is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, self-administered injection dosed as infrequently as once every two weeks. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative p...